Navigation Links
Visikol Machine Learning Digital Pathology Services for Drug Discovery
Date:10/16/2018

Since the inception of the microscope, researchers and clinicians have characterized tissues through the visualization of histopathology slides by eye wherein key features are used for classification. While this type of human driven approach is the gold standard for diagnosis and research, it is highly limited in that it is a qualitative and low-throughput approach where only a few features are used for characterization from a small region of interest.

This field of pathology is ripe for disruption as advances in computer vision and data processing now allow for thousands of tissues to be analyzed per day by a computer that evaluates not only a few features, but thousands of features from an entire slide in a quantitative manner. “The ability to evaluate large numbers of features from a single slide means that we can start to identify unique biomarkers such as the circularity of nuclei being correlated to a specific disease phenotype. Computer vision provides the ability to find novel biomarkers that a human could never even consider” described Visikol Chief Science Officer Dr. Thomas Villani. Traditionally, the way pathologists interpret slides is to look for tissue specific features that they have learned from their studies and practical experience. The major benefit of a computer-based approach is that instead of relying on a pathologist’s memory and training, a slide can be compared to vast archives of digital slides and their corresponding metadata.

As a pre-clinical drug discovery contract research organization, Visikol has always been focused on transforming tissues and cells into quantitative insights for clients. Initially, Visikol focused predominantly on 3D tissue imaging through the use of tissue clearing, but has since expanded into the digital pathology, high content screening and 3D cell culture assay fields. “We originally developed digital pathology tools for use with very large three-dimensional data sets that we were generating from tissues using light sheet or confocal microscopy. After using these approaches for a wide range of applications, we realized that our digital pathology approach could also be used in a two-dimensional context with traditional 2D H&E, IHC and FISH slides” explained Visikol Chief Executive Officer Dr. Michael Johnson.

In 2018, Visikol began partnering with pharmaceutical companies to offer its 3Screen™ digital pathology tools for use in their drug discovery efforts. Visikol partners with pharmaceutical companies wherein they send boxes of glass microscope slides or hard drives of scanned slides for analysis by Visikol who transforms these raw data sets into actionable insights. “We see digital pathology as a transformational change for drug discovery as it allows pharmaceutical companies to acquire better and more accurate data from tissues while leveraging huge data sets to identify novel correlations or biomarkers. Ultimately, tissues are just data sets and by digitizing this data we can now make use of advanced analysis techniques that allow us to ask and answer more complex research questions” described Dr. Johnson.

In offering digital pathology services to pharmaceutical companies, Visikol is agnostic about the type of tissue it is working with and focuses entirely on how best to answer a client’s research question. The projects that Visikol works on for clients range from simple area or scoring quantification to developing regulated machine learning digital pathology software for use with patients. Recently, Visikol announced its collaboration with Enzyvant Therapeutics through which it leveraged its 3Screen™ digital pathology services to develop a digital pathology quality control assay to support the introduction of RVT-802 (i.e. transplantable thymus tissue). Such machine learning projects require that clients have detailed histological databases but enable for an in depth understanding of what specific tissue properties effect a disease phenotype. Regardless of the project, Visikol works closely with clients to understand their needs and builds a customized approach to address their research question and desired end-points.

About Visikol
Visikol is a contract research organization that is focused on accelerating drug discovery through the transformation of tissues into actionable and quantitative insights. Visikol is comprised of experts in imaging, digital pathology, machine learning and advanced in vitro models. The company leverages this expertise along with a portfolio of proprietary imaging and image analysis technologies to offer pharmaceutical/biotech clients its 3Screen™ services which are comprised of 3D cell culture assays, digital pathology services, 3D tissue imaging services, high content screening and customized drug discovery solutions. Visikol partners closely with clients in drug discovery efforts and to assist them with using innovative assays for drug screening that are more rapid, reliable, and relevant for screening. In addition to this service offering, Visikol also sells various tissue clearing reagents and kits for researchers that are interested in adopting 3D tissue imaging into their own workflows. For more information about Visikol or its 3Screen™ services, please visit our website at visikol.com.

For additional assistance, journalists, investors and analysts may contact:
Dr. Michael Johnson
CEO and Co-Founder
info@visikol.com
1-800-615-8474

Read the full story at https://www.prweb.com/releases/visikol_machine_learning_digital_pathology_services_for_drug_discovery/prweb15829643.htm.


'/>"/>
Source: PRWeb
Copyright©2018 Vocus, Inc.
All rights reserved


Related biology technology :

1. Dr. Michael Johnson, CEO and Co-founder of Visikol, Invited to Speak with Governor Murphy on Behalf of the Science, Innovation, and Technology Commission Bill
2. Ribbon Cutting and Open House at Milwaukee Area Technical College on Oct. 17 to Spotlight New CNC Swiss Machinery and Expanded Instructional Capacity
3. Franz’s Gruff Adds “Time Machine” Feature for Temporal Graph Analytics
4. Microscan To Demonstrate Advancements in Barcode and Machine Vision Technology at AACC Clinical Lab Expo 2017
5. 2017 Foresight Fellows Announced in Molecular Machines, Space, Longevity, Artificial Intelligence
6. FireflySci Develops New Agilent Flow Cell Line for HPLC Machines
7. Wearable Tech + Digital Tech + NeuroTech NYC: Sensors - Data - AI - BCI - Machine Learning - VR/AR in health
8. Morris Midwest Will Hold an Open House and CNC Machine Tool Show in Maple Grove, Minnesota, May 11-12 for Manufacturers of Precision Machined Parts
9. Talon Innovations Corporation Acquires Vulcan Machine, Inc.
10. MachineShop Internet of Things (IoT) Platform Selected by Milwaukee Instruments to Power Its New Web-Enabled Water Monitoring Solution
11. Global PDT Machine Industry Report 2014
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/7/2019)... ... January 07, 2019 , ... Kainos ... its Parkinson's Disease drug candidate, code-named "KM-819." KM-819 is an orally active ... took place in South Korea. , This Phase 1 randomized, double-blind, placebo-controlled ...
(Date:1/4/2019)... ... January 03, 2019 , ... Calidi Biotherapeutics, Inc., ... today announced the founding of a scientific and medical advisory board (SMAB). The ... leaders in the Immuno-Oncology field. The founding members of Calidi Biotherapeutics SMAB include ...
(Date:12/18/2018)... ... 17, 2018 , ... ABCT , the Accelerator for ... to participate in the annual program. Twelve ventures will participate in the 6.5-month-long ... network. All startups receive an entrepreneur coach, access to active business professionals and ...
(Date:12/13/2018)... ... December 11, 2018 , ... ... and nurses can use to quickly detect Clostridium difficile (C. diff), a dangerous ... of a handheld device that can be used onsite in doctor’s offices and ...
Breaking Biology Technology:
(Date:12/13/2018)... ... 13, 2018 , ... Biocompare, the leading online information resource ... Need to Know about Antibody Manufacturing” . This educational resource is the third ... this film is to educate scientists about antibody production, validation, and responsible sourcing. ...
(Date:12/6/2018)... ... , ... Stewart has been on the business side of ... During his recent five-year tenure with InSphero he was the US General Manger ... in Brunswick, Maine. Through these experiences, Stewart has a deep understanding of the ...
(Date:12/5/2018)... ... December 03, 2018 , ... uBiome, the leader in microbial ... the Division of Gastroenterology and Hepatology at UC San Diego and staff gastroenterologist ... the board of leading scientists and doctors from around the world, Dr. Zarrinpar ...
Breaking Biology News(10 mins):